The goal of this randomized, double-blind, placebo-controlled study is to assess whether the food supplement Endocalyx lowers blood pressure in patients with treatment resistant hypertension.
Treatment resistant hypertension defined as
an uncontrolled office BP (≥140/90 mmHg).
is on a regimen of ≥3 adequately dosed antihypertensive agents of different classes, including a diuretic, at maximum tolerated dose based on investigator judgment.
Stable diuretic and antihypertensive treatment for the previous 3 weeks.
Age <18 years.
Estimated glomerular filtration rate (eGFR) <20 ml/min/1.73m2 measured by the 2021 Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) creatinine formula and the 2012 cystatin C CKD-EPI formula.
A mean seated systolic blood pressure of at least 180 mmHg or a diastolic blood pressure of at least 110 mmHg.
Known secondary hypertension
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Lead sponsor
Dutch Heart Foundation
Collaborator
Dutch Kidney Foundation
Collaborator
Microvascular Health Solutions LLC
Collaborator